Videos

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss the financial barriers facing patients with geographic atrophy, including Medicare coverage limitations, out-of-pocket costs, and the role of assistance programs such as Good Days in expanding treatment access.

Dhoot discusses the full results of the 5-year GALE extension study of pegcetacoplan in patients with GA secondary to age-related macular degeneration.

In this second case, Dr. Maria Berrocal presents a patient with severe, refractory diabetic macular edema (DME) who had received 13 prior anti-VEGF injections (bevacizumab and aflibercept) with persistent fluid and legal blindness (20/200 vision).

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss how retina specialists identify appropriate candidates for complement inhibitor therapy in geographic atrophy, set patient expectations, and monitor treatment in real-world clinical practice.

Joseph A. Anaya, MD, MBA, and Ashkan M. Abbey, MD, FASRS, FAAO, consider how emerging treatments impact patient vision, functional outcomes, and practical management of geographic atrophy.

In this opening segment, Dr. Maria Berrocal introduces a case-based discussion on real-world management of diabetic macular edema (DME), with a focus on improving retinal drying, extending durability, and reducing patient burden.

Take a look at some, but certainly not all, that you may have missed from this year’s EnVision Summit.

Phase 1b data show KSI-101 rapidly clears inflammatory macular edema, delivers long-lasting fluid control without steroids, and advances into enrolling phase 3 trials.

Join Douglas D. Koch, MD, and Liliana Werner, MD, PhD, as they break down acrylic and silicone intraocular lenses, discuss material-specific risks, and explore the future of lens technology in this inaugural episode.

Inder Paul Singh, MD, discusses his practice's approach to office-based surgery.

McCabe, MD, presented alongside P. Dee Stephenson, MD, FACS, for the product theater titled "Know Your Dry Eye: Navigating the Challenges of Real-World Dry Eye Cases."

Rahul Tonk, MD, MBA, gives an overview of the cases he discussed during his portion of a segment on refractive surgery.

Nicole Bajic, MD, outlines key takeaways from her case study involving Descemet membrane detachment occurring in the setting of focal canaloplasty using the Streamline Surgical System.

Pathik P. Amin, OD, FAAO, details his segment of an educational track session on glaucoma at this year's conference.

Shameema Sikder, MD, details a session she presented with Roomasa Channa, MD, at EnVision Summit 2026.

Bonnie An Henderson, MD, founder of EnVision Summit, highlights how the annual conference integrates MD and OD tracks, practical subspecialty updates, and structured opportunities for connection across career stages.

Oluwatosin U. Smith, MD, highlights how the foundation provides education, research, and access-to-care for patients and clinicians globally and locally.

NYU Grossman’s Preeya Mehta, MD, and Jonathan S. Williams, MD, sit down with Mount Sinai’s Louis R. Pasquale, MD, to discuss long-term safety and efficacy data from a PreserFlo microshunt trial and the role of microshunts in glaucoma surgery.

Andrew Tatham, MD, MBA, FRCOphth, FEBO, outlines the role of micro-invasive glaucoma surgery alongside established glaucoma procedures, focusing on safety, patient selection, and future directions.

Prof. Dr. med. Wolf A. Lagrèze highlights the clinical role, limitations, and future potential of optical coherence tomography in glaucoma and neuro-ophthalmic disease.

Panelists discuss how emerging therapies—including TKIs, sustained-release implants, and gene therapy—may reduce treatment burden and shift retinal disease management toward longer-acting, maintenance-based approaches.

Their conversation focuses on anatomy-driven, individualized approaches and multidisciplinary decision-making for patients with neovascular glaucoma.

Panelists discuss how aflibercept 8 mg maintains a safety profile similar to 2 mg and how workflow, systemic risk, and patient comfort influence confidence in adopting the higher-dose formulation.

Panelists discuss how clinicians manage suboptimal responders by focusing on stability rather than complete dryness, using multimodal approaches, and avoiding premature treatment switching.

Jennifer E. Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians should monitor children when considering adalimumab discontinuation.

Oluwatosin U. Smith, MD, highlights the practical impact of expanding tools on real-world glaucoma treatment.

Panelists discuss how trial findings for aflibercept 8 mg and faricimab in RVO demonstrate comparable efficacy and durability, with treatment selection ultimately guided by patient characteristics and future labeling.

Panelists discuss how pivotal RVO trial data for aflibercept 8 mg show strong durability and visual outcomes while raising questions about long-term disease chronicity and vascular remodeling under sustained VEGF suppression.